New drug could scratch the itch for dialysis patients
NCT ID NCT07526324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether the drug difelikefalin can reduce severe itching in people with chronic kidney disease who are on hemodialysis. About 106 adults will receive either the drug or a placebo after each dialysis session for 6 weeks. The main goal is to see if itching scores improve, with a focus on safety and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Difelikefalin injection
- What this could lead to
- If it works, this could provide a new option to relieve severe itching in people on dialysis, improving their quality of life.
- What could go wrong
- This is a small, early-stage trial with only 106 participants. The drug may not prove more effective than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD 5D, HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.